US6652882B1
(en)
*
|
1997-10-06 |
2003-11-25 |
Intellipharmaceutics Corp |
Controlled release formulation containing bupropion
|
US6221917B1
(en)
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
EP1051166A1
(en)
*
|
1998-01-29 |
2000-11-15 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (+) -bupropion
|
WO1999038503A1
(en)
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Pharmacological uses of optically pure (+)-bupropion
|
JP2002501892A
(ja)
|
1998-01-29 |
2002-01-22 |
セプラコア インコーポレーテッド |
光学的に純粋な(−)−ビュープロピオンの薬学的使用
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
AU4841599A
(en)
*
|
1998-06-29 |
2000-01-17 |
Pharmaceuticals Applications Asociates, Llc |
Methods and transdermal compositions for pain relief
|
US6238697B1
(en)
*
|
1998-12-21 |
2001-05-29 |
Pharmalogix, Inc. |
Methods and formulations for making bupropion hydrochloride tablets using direct compression
|
US6855820B2
(en)
*
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6210716B1
(en)
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6312716B1
(en)
*
|
1999-05-10 |
2001-11-06 |
Peierce Management Llc |
Patch and method for transdermal delivery of bupropion base
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
EP1284729A4
(en)
*
|
2000-04-13 |
2007-12-19 |
Mayo Foundation |
REDUCTION AGENTS OF A (BETA) 42
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
US6333332B1
(en)
*
|
2000-08-25 |
2001-12-25 |
Impax Laboratories, Inc. |
Stabilized pharmaceutical compositions containing bupropion hydrochloride
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
EP2266590A3
(en)
|
2002-02-22 |
2011-04-20 |
Shire LLC |
Active agent delivery sytems and methods for protecting and administering active agents
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
US7109198B2
(en)
*
|
2002-05-17 |
2006-09-19 |
Duke University |
Method for treating obesity
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
US20040191298A1
(en)
*
|
2003-03-26 |
2004-09-30 |
Fredrik Nicklasson |
New formulations and use thereof
|
EP2316456B1
(en)
|
2003-04-29 |
2017-06-14 |
Orexigen Therapeutics, Inc. |
Compositions for affecting weight loss comprising an opioid antagonist and bupropion
|
EP1651195A4
(en)
*
|
2003-07-11 |
2007-10-03 |
Myriad Genetics Inc |
PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
EP1734955A2
(en)
|
2004-01-13 |
2006-12-27 |
Duke University |
Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
US20060100205A1
(en)
*
|
2004-04-21 |
2006-05-11 |
Eckard Weber |
Compositions for affecting weight loss
|
EP1745180A1
(en)
*
|
2004-04-29 |
2007-01-24 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
US20060099262A1
(en)
*
|
2004-11-08 |
2006-05-11 |
Biokey, Inc. |
Methods and formulations for making controlled release oral dosage form
|
US8586085B2
(en)
*
|
2004-11-08 |
2013-11-19 |
Biokey, Inc. |
Methods and formulations for making pharmaceutical compositions containing bupropion
|
KR100670798B1
(ko)
|
2004-12-17 |
2007-01-17 |
한국전자통신연구원 |
데이터베이스 캐시 시스템
|
US20060204571A1
(en)
*
|
2005-03-12 |
2006-09-14 |
Sun Pharmaceutical Industries Limited |
Stable compositions of bupropion or its pharmaceutically acceptable salts
|
NZ561375A
(en)
|
2005-06-27 |
2011-06-30 |
Biovail Lab Int Srl |
Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
|
BRPI0613611A2
(pt)
*
|
2005-07-22 |
2011-01-18 |
Myriad Genetics Inc |
formulações de alta concentração de fármaco e formas de dosagens
|
EP1954257A4
(en)
*
|
2005-10-14 |
2009-05-20 |
Lundbeck & Co As H |
METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
|
JP2009511607A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤
|
EP1951212A2
(en)
|
2005-11-22 |
2008-08-06 |
Orexigen Therapeutics, Inc. |
Compositions and methods for increasing insulin sensitivity
|
DK1954241T3
(da)
*
|
2005-11-28 |
2012-06-18 |
Orexigen Therapeutics Inc |
Zonisamid-formulering med vedvarende frigivelse
|
WO2007101225A2
(en)
*
|
2006-02-27 |
2007-09-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods to identify inhibitors of the unfolded protein response
|
US8916195B2
(en)
*
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
EP2029135A4
(en)
|
2006-06-13 |
2011-08-17 |
Univ Leland Stanford Junior |
EPOXY HEMMER OF CYSTONE PROTEASES
|
EP2046119A2
(en)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
KR100843021B1
(ko)
*
|
2006-09-11 |
2008-07-01 |
주식회사 드림파마 |
안정성이 개선된 디에틸프로피온 하이드로클로라이드를포함하는 경구투여용 고형 제제
|
KR20090090316A
(ko)
|
2006-11-09 |
2009-08-25 |
오렉시젠 세러퓨틱스 인크. |
체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
|
TW201811315A
(zh)
|
2006-11-09 |
2018-04-01 |
美商歐瑞根治療有限公司 |
層狀醫藥調配物
|
EP2455076A1
(en)
|
2007-04-09 |
2012-05-23 |
Sepracor Inc. |
Compositions comprising desvenlafaxine for use in treating sleep-related breathing disorders
|
US9339500B2
(en)
*
|
2008-03-04 |
2016-05-17 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
CA2725930A1
(en)
|
2008-05-30 |
2009-12-30 |
Orexigen Therapeutics, Inc. |
Methods for treating visceral fat conditions
|
TW201039815A
(en)
|
2009-04-13 |
2010-11-16 |
Resolvyx Pharmaceuticals Inc |
Compositions and methods for the treatment of inflammation
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
ES2762113T3
(es)
|
2010-01-11 |
2020-05-22 |
Nalpropion Pharmaceuticals Inc |
Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
|
KR20140027907A
(ko)
|
2010-10-11 |
2014-03-07 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
치환된 벤즈아미드 및 그의 용도
|
KR101534606B1
(ko)
*
|
2011-11-08 |
2015-07-10 |
알보젠코리아 주식회사 |
사포그릴레이트의 안정화된 지속 방출 제제
|
EA026656B1
(ru)
|
2011-11-21 |
2017-05-31 |
Калитера Байосайенсиз Инк. |
Гетероциклические ингибиторы глютаминазы
|
AU2013245809A1
(en)
|
2012-04-12 |
2014-11-06 |
Auckland Uniservices Limited |
Substituted benzamides and their uses
|
EP4104824A1
(en)
|
2012-06-06 |
2022-12-21 |
Nalpropion Pharmaceuticals LLC |
Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
|
SI2920168T1
(sl)
|
2012-11-16 |
2022-01-31 |
Calithera Biosciences, Inc. |
Zaviralci heterociklične glutaminaze
|
US10100037B2
(en)
|
2013-03-15 |
2018-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Activity-based probe compounds, compositions, and methods of use
|
US11324670B2
(en)
*
|
2013-10-16 |
2022-05-10 |
Bilal Walk |
Cocoa butter powdered moisturizer
|
US11969421B2
(en)
|
2013-11-05 |
2024-04-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
WO2015192014A1
(en)
|
2014-06-13 |
2015-12-17 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors
|
EP3193876B1
(en)
|
2014-08-07 |
2022-01-12 |
Calithera Biosciences Inc. |
Crystal forms of glutaminase inhibitors
|
AR101558A1
(es)
|
2014-08-13 |
2016-12-28 |
Eolas Therapeutics Inc |
Difluoropirrolidinas como moduladores del receptor de orexina
|
WO2016070063A1
(en)
|
2014-10-31 |
2016-05-06 |
The Regents Of The University Of California |
Compositions and methods for treating hiv-associated cognitive dysfunction
|
KR101612197B1
(ko)
*
|
2014-11-25 |
2016-04-14 |
알보젠코리아 주식회사 |
부프로피온 염산염을 함유하는 안정화된 정제 및 이의 제조방법
|
EP3267984B1
(en)
|
2015-03-10 |
2021-11-24 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
US10143699B2
(en)
|
2015-06-23 |
2018-12-04 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
GB2542881B
(en)
|
2015-10-02 |
2020-01-01 |
Carr Andrew |
Crystal forms of ß-nicotinamide mononucleotide
|
SG11201802830QA
(en)
|
2015-10-05 |
2018-05-30 |
Calithera Biosciences Inc |
Combination therapy with glutaminase inhibitors and immuno-oncology agents
|
UA125289C2
(uk)
|
2015-10-30 |
2022-02-16 |
Калітера Байосайєнсиз, Інк. |
Композиції і способи для інгібування активності аргінази
|
MX2018005872A
(es)
|
2015-11-16 |
2019-05-16 |
Ichorion Therapeutics Inc |
Profarmacos de acido nucleico.
|
TWI710557B
(zh)
|
2016-02-12 |
2020-11-21 |
美商伊歐拉斯治療學公司 |
作為食慾素受體調節劑之經鹵素取代之六氫吡啶
|
WO2017210565A1
(en)
|
2016-06-03 |
2017-12-07 |
Prisident And Fellows Of Harvard College |
Antifungal compounds
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
US10472364B2
(en)
|
2016-09-09 |
2019-11-12 |
Calithera Biosciences, Inc. |
Ectonucleotidase inhibitors and methods of use thereof
|
WO2018049094A1
(en)
|
2016-09-09 |
2018-03-15 |
The Regents Of The University Of California |
Estrogen receptor ligands, compositions and methods related thereto
|
AU2017330443B2
(en)
|
2016-09-26 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Chromobox protein inhibitors and uses thereof
|
MX2019003623A
(es)
|
2016-09-28 |
2019-09-23 |
Medicon Pharmaceuticals Inc |
Composiciones y metodos para el tratamiento de afecciones oftalmicas.
|
FI3519050T3
(fi)
|
2016-09-28 |
2023-07-27 |
Medicon Pharmaceuticals Inc |
Koostumuksia silmätautien hoitamiseksi
|
WO2018089490A1
(en)
|
2016-11-08 |
2018-05-17 |
Calithera Biosciences, Inc. |
Arginase inhibitor combination therapies
|
LT3559009T
(lt)
|
2016-12-22 |
2021-06-25 |
Calithera Biosciences, Inc. |
Kompozicijos ir būdai, skirti arginazės aktyvumo slopinimui
|
AU2017382460A1
(en)
|
2016-12-23 |
2019-05-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Activity-based probe compounds, compositions, and methods of use
|
WO2018136634A1
(en)
|
2017-01-18 |
2018-07-26 |
Vanderbilt University |
Fused heterocyclic compounds as selective bmp inhibitors
|
BR112019017567A2
(pt)
|
2017-02-24 |
2020-03-24 |
Merck Patent Gmbh |
Derivados de 1,4,6-trissubstituído-2-alquil-1h-benzo[d]imidazol como inibidores da di-hidro-orotato oxigenase
|
EP4252853A3
(en)
|
2017-03-31 |
2023-12-13 |
Aurigene Oncology Limited |
Compounds and compositions for treating hematological disorders
|
US10994025B2
(en)
|
2017-05-12 |
2021-05-04 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded RNA complexes and uses related thereto
|
US11325943B2
(en)
|
2017-06-02 |
2022-05-10 |
Stealth Biotherapeutics Inc. |
Crystalline salt forms of SBT-20
|
US10526334B2
(en)
|
2017-07-19 |
2020-01-07 |
California Institute Of Technology |
Methods for preparing bis-tetrahydroisoquinoline-containing compounds
|
SG11202003081WA
(en)
|
2017-10-11 |
2020-05-28 |
Aurigene Discovery Tech Ltd |
Crystalline forms of 3-substituted 1,2,4-oxadiazole
|
IL308364A
(en)
|
2017-10-31 |
2024-01-01 |
Curis Inc |
Compounds and preparations for the treatment of hematological disorders
|
JP7378394B2
(ja)
|
2017-11-03 |
2023-11-13 |
オーリジーン オンコロジー リミテッド |
Tim-3およびpd-1経路の二重阻害剤
|
JP7378395B2
(ja)
|
2017-11-06 |
2023-11-13 |
オーリジーン オンコロジー リミテッド |
免疫調節のためのコンジョイントセラピー
|
CN111491922A
(zh)
|
2017-12-22 |
2020-08-04 |
免疫医疗有限公司 |
Keap1的BTB结构域的小分子调节剂
|
US10745400B2
(en)
|
2018-03-14 |
2020-08-18 |
Vanderbuilt University |
Inhibition of BMP signaling, compounds, compositions and uses thereof
|
WO2019200274A1
(en)
|
2018-04-12 |
2019-10-17 |
MatRx Therapeutics Corporation |
Compositions and methods for treating elastic fiber breakdown
|
WO2019217450A1
(en)
|
2018-05-08 |
2019-11-14 |
Rhode Island Hospital |
Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
|
WO2020006489A1
(en)
|
2018-06-29 |
2020-01-02 |
The Regents Of The University Of California |
New molecular tweezers against neurological disorders and viral infections
|
AU2019310595B2
(en)
|
2018-07-27 |
2022-11-24 |
1200 Pharma Llc |
CDK inhibitors and uses thereof
|
JP2021535181A
(ja)
|
2018-09-05 |
2021-12-16 |
ザ ジェネラル ホスピタル コーポレイション |
サイトカイン放出症候群を処置する方法
|
WO2020086963A1
(en)
|
2018-10-26 |
2020-04-30 |
Keros Therapeutics |
Crystal forms of an alk2 inhibitor
|
MX2021008533A
(es)
|
2019-01-18 |
2021-08-19 |
Astrazeneca Ab |
Inhibidores de la pcsk9 y metodos de uso de los mismos.
|
CA3125991A1
(en)
|
2019-01-25 |
2020-07-30 |
Brown University |
Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
|
AU2020214626A1
(en)
|
2019-01-31 |
2021-09-16 |
Elektrofi, Inc. |
Particle formation and morphology
|
BR112021017960A2
(pt)
|
2019-03-14 |
2021-11-23 |
Astrazeneca Ab |
Lanabecestate para perda de peso
|
WO2020246503A1
(ja)
|
2019-06-03 |
2020-12-10 |
株式会社大分大学先端医学研究所 |
狂犬病治療のための環状アミド化合物およびその方法
|
CN110200947A
(zh)
*
|
2019-06-27 |
2019-09-06 |
深圳市泛谷药业股份有限公司 |
一种安非他酮肠溶缓释微丸胶囊及其制备方法
|
JP2022547546A
(ja)
|
2019-09-13 |
2022-11-14 |
エレクトロフィ,インコーポレイテッド |
疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
|
BR112022009202A2
(pt)
|
2019-11-12 |
2022-09-06 |
Genzyme Corp |
Heteroarilaminosulfonamidas de 6 membros para tratamento de doenças e condições mediadas por atividade deficiente de cftr
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
US20230088747A1
(en)
|
2019-12-16 |
2023-03-23 |
Unist (Ulsan National Institute Of Science And Technology) |
Compounds for inhibiting neovascularization factors and use thereof
|
WO2021158959A2
(en)
|
2020-02-07 |
2021-08-12 |
Elektrofi, Inc. |
Peptide particles and methods of formation
|
US20230065628A1
(en)
|
2020-02-19 |
2023-03-02 |
Elektrofi, Inc. |
Droplet Formation and Particle Morphology
|
EP4135667A1
(en)
|
2020-04-17 |
2023-02-22 |
Elektrofi, Inc. |
Methods of forming particles by continuous droplet formation and dehydration
|
WO2021263072A1
(en)
|
2020-06-25 |
2021-12-30 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating disease
|
EP4192811A1
(en)
|
2020-08-10 |
2023-06-14 |
Dana-Farber Cancer Institute, Inc. |
Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
|
EP4192817A1
(en)
|
2020-08-10 |
2023-06-14 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
US20230365583A1
(en)
|
2020-08-10 |
2023-11-16 |
Dana-Farber Cancer Institute, Inc. |
Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
|
CN116323571A
(zh)
|
2020-10-23 |
2023-06-23 |
丹娜法伯癌症研究院 |
肌酸激酶(ck)的共价抑制剂以及其用于治疗和预防癌症的用途
|
AU2021390502A1
(en)
|
2020-12-01 |
2023-06-22 |
Antecip Bioventures Ii Llc |
Bupropion and dextromethorphan for reduction of suicide risk in depression patients
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
MX2023007450A
(es)
|
2020-12-21 |
2023-10-05 |
Univ Cornell |
Sistema de administración de fármacos ligados a péptidos.
|
US20240132480A1
(en)
|
2021-01-08 |
2024-04-25 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
EP4396176A1
(en)
|
2021-09-03 |
2024-07-10 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
EP4396179A1
(en)
|
2021-09-03 |
2024-07-10 |
Genzyme Corporation |
Indole compounds and methods of use
|
KR20240095536A
(ko)
|
2021-10-01 |
2024-06-25 |
뉴베일런트, 아이엔씨. |
헤테로방향족 매크로사이클릭 에테르 화합물을 사용한 고형 종양의 치료 방법
|
IL311444A
(en)
|
2021-10-01 |
2024-05-01 |
Nuvalent Inc |
Solid forms, pharmaceutical preparations and preparation of macrocyclic heteroaromatic ether compounds
|
WO2023187422A1
(en)
|
2022-03-31 |
2023-10-05 |
Revolo Biotherapeutics Limited |
Compositions and their use in methods for treating intestinal inflammation
|
US20230322797A1
(en)
|
2022-04-07 |
2023-10-12 |
Nuvalent, Inc. |
Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
|
WO2023196910A1
(en)
|
2022-04-07 |
2023-10-12 |
Nuvalent, Inc |
Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
|
WO2023212721A1
(en)
|
2022-04-29 |
2023-11-02 |
Elektrofi, Inc. |
Injectable suspensions
|
WO2023223015A1
(en)
|
2022-05-16 |
2023-11-23 |
Revolo Biotherapeutics Limited |
Methods and compositions for preventing or treating food allergies
|
WO2023250157A1
(en)
|
2022-06-24 |
2023-12-28 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
US11717518B1
(en)
|
2022-06-30 |
2023-08-08 |
Antecip Bioventures Ii Llc |
Bupropion dosage forms with reduced food and alcohol dosing effects
|
WO2024006812A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising bupropion and cysteine
|
WO2024006853A1
(en)
|
2022-06-30 |
2024-01-04 |
Antecip Bioventures Ii Llc |
Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
|
US11844797B1
(en)
|
2023-04-20 |
2023-12-19 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
US11730706B1
(en)
|
2022-07-07 |
2023-08-22 |
Antecip Bioventures Ii Llc |
Treatment of depression in certain patient populations
|
WO2024013209A1
(en)
|
2022-07-13 |
2024-01-18 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
WO2024036098A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds
|
WO2024036097A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds and isotopologues thereof
|
WO2024086634A1
(en)
|
2022-10-19 |
2024-04-25 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether chemotherapeutic agents
|